Literature DB >> 19890130

Myelodysplastic syndromes.

Ayalew Tefferi1, James W Vardiman.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19890130     DOI： 10.1056/NEJMra0902908

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  239 in total

1.  Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Authors:  Elias Jabbour; Nicholas J Short; Guillermo Montalban-Bravo; Xuelin Huang; Carlos Bueso-Ramos; Wei Qiao; Hui Yang; Chong Zhao; Tapan Kadia; Gautam Borthakur; Naveen Pemmaraju; Koji Sasaki; Zeev Estrov; Jorge Cortes; Farhad Ravandi; Yesid Alvarado; Rami Komrokji; Mikkael A Sekeres; David P Steensma; Amy DeZern; Gail Roboz; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  Exploring the variation within.

Authors:  Evan Z Macosko; Steven A McCarroll
Journal:  Nat Genet       Date:  2012-05-29       Impact factor: 38.330

3.  Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

4.  Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Authors:  Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2010-09-22       Impact factor: 7.616

5.  Investigation of DNA repair gene variants on myelodysplastic syndromes in a Turkish population.

Authors:  Mehmet Burak Aktuglu; Mesut Ayer; Elif S Bireller; Cagla Rencuzogullari; Hasan Acik; Zeynep Karaali; Taner Alioglu; Namik Yigit; Mustafa Velet; Eray Atalay; Oznur Sari Ure; Bedia Cakmakoglu
Journal:  Med Oncol       Date:  2014-08-26       Impact factor: 3.064

6.  Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.

Authors:  Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

7.  LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.

Authors:  Alix Dubois; Nathan Furstoss; Patrick Auberger; Guillaume Robert; Anne Calleja; Marwa Zerhouni; Thomas Cluzeau; Coline Savy; Sandrine Marchetti; Mohamed Amine Hamouda; Sonia Boulakirba; François Orange; Sandra Lacas-Gervais; Jean-Michel Karsenti; Nicolas Mounier; Jérôme Tamburini; Alexandre Puissant; Frederic Luciano; Arnaud Jacquel
Journal:  Leukemia       Date:  2019-01-03       Impact factor: 11.528

8.  Alcohol use is not a significant contributor to myelodysplastic syndromes.

Authors:  Elizabeth A Duffy; Phuong L Nguyen; Adina Cioc; Erica Warlick; Michelle A Roesler; Jenny N Poynter
Journal:  Cancer Causes Control       Date:  2020-04-13       Impact factor: 2.506

9.  Parenchymal signal intensity in 3-T body MRI of dogs with hematopoietic neoplasia.

Authors:  Daniel A Feeney; Leslie C Sharkey; Susan M Steward; Katherine L Bahr; Michael S Henson; Daisuke Ito; Timothy D O'Brien; Carl R Jessen; Brian D Husbands; Antonella Borgatti; Jaime F Modiano
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

10.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.